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Abstract
Background: Brain-derived neurotrophic factor (BDNF) is an activity-dependent secreted protein that is critical to
organization of neuronal networks and synaptic plasticity, especially in the hippocampus. We tested hypothesis that
reduced CSF BDNF is associated with age-related cognitive decline.
Methodology/Principal Findings, and Conclusions/Significance: CSF concentration of BDNF, Ab42 and total tau were
measured in 128 cognitively normal adults (Normals), 21 patients with Alzheimer’s disease (AD), and nine patients with Mild
Cognitive Impairment. Apolipoprotein E and BDNF SNP rs6265 genotype were determined. Neuropsychological tests were
performed at baseline for all subjects and at follow-up visits in 50 Normals. CSF BDNF level was lower in AD patients
compared to age-matched Normals (p=0.02). CSF BDNF concentration decreased with age among Normals and was higher
in women than men (both p,0.001). After adjusting for age, gender, education, CSF Ab42 and total tau, and APOE and BDNF
genotypes, lower CSF BDNF concentration was associated poorer immediate and delayed recall at baseline (both p,0.05)
and in follow up of approximately 3 years duration (both p,0.01).
Conclusions/Significance: Reduced CSF BDNF was associated with age-related cognitive decline, suggesting a potential
mechanism that may contribute in part to cognitive decline in older individuals.
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Introduction
Age-related cognitive decline is a complex convergent pheno-
type that likely derives in part from brain senescence and in part
from prodromal dementing illnesses, most commonly Alzheimer’s
disease (AD). Brain-derived neurotrophic factor (BDNF) is an
activity-dependent secreted protein that, along with its receptors, is
expressed widely in the central nervous system and is critical to
organization of neuronal networks and synaptic plasticity,
especially in the hippocampus, in a variety of animal models
and apparently in humans [1,2]. Although controversy remains,
these human data derive mostly from investigations of an allelic
variant of BDNF (Val66Met or Met-BDNF), inheritance of which
has been associated with poorer cognitive performance in healthy
older adults [3], impaired memory in patients with schizophrenia
and healthy controls [1,2], abnormal hippocampal activation as
assessed by fMRI [2], and an approximately 4% to 11% smaller
hippocampal volume as determined by MRI in healthy adult
volunteers [3,4]. The mechanisms that underlie these associations
of functional and structural differences with inheritance of Met-
BDNF are not clear; however, one study has shown diminished
depolarization-induced secretion of Met-BDNF compared to Val-
BDNF, and failure of Met-BDNF to localize to secretory granules or
synapses in transfected neurons [2]. Together, these findings have
led to the hypothesis that reduced BDNF secretion is one
mechanism of age-related cognitive decline. We are unaware of
any published study that has yet tested this hypothesis.
Methods
All procedures were approved by the institutional review boards
of the University of Washington; all subjects were recruited from
University of Washington Alzheimer’s Disease Research Center
and provided written informed consent. Subjects underwent
detailed clinical and laboratory evaluation and were classified as
no cognitive impairment (Normals), amnestic mild cognitive
PLoS ONE | www.plosone.org 1 May 2009 | Volume 4 | Issue 5 | e5424impairment (MCI) [5], or probable AD [6]. Inclusion and
exclusion criteria, method of CSF collection, and analysis were
exactly as previously described [7].
CSF concentration of BDNF, total tau and Ab42 was measured
using an X-MAP-based assay [7]. APOE genotype was determined
by a restriction digest method [8]. BDNF SNP rs6265 was
genotyped using TaqMan allelic discrimination detection, as
previously described [9].
Neuropsychological tests included: (i) Paragraph Recall - a test
of declarative memory [10,11]. Paragraphs were modeled after the
Logical Memory subtests I and II of the WMS-R [12]. Total score
for immediate recall and delayed recall (each with possible range
0–25) were used. (ii) Category Fluency - a test of semantic memory
[13]. Total number of unique animals named in 60 seconds was
used. (iii) Trail Making Test, Parts A and B - test of ability to adapt
to shifting task demands. Time taken to complete Part B (upper
bound of 300 sec), a measure of executive function [14], was used.
One-way analysis of variance (ANOVA) was used with post hoc
Bonferroni multiple pair-wise comparisons for continuous vari-
ables and Fisher’s exact test for categorical variables to assess
differences between diagnostic and genetic groups. Linear
regression models were used for associations of demographic
characteristics with CSF BDNF concentration, and cross-sectional
relationships between CSF BDNF concentration and coincident
cognitive test performance. Raw scores were used for each test
except log-transformed times for Trails B to remove skewness. We
used two-stage regression (least squares slope for each test in each
individual over time, then weighted regression model with slope as
response variable) to assess association of baseline CSF BDNF
concentration with subsequent longitudinal changes of cognitive
test performance [15]. Weights were based on subjects having
different numbers of follow-up visits at different times after
baseline. Statistical analyses were performed using S-PLUS
version 8.0 [16] and R version 2.7.1 [17].
Results
Age-matched Normals, MCI, and AD
Table 1 presents demographics and baseline CSF BDNF levels
in 128 normal controls (Normals), 9 MCI and 21 AD patients. To
compare measures between these three groups after adjusting for
age, a subset of the Normals (n=76) age$50 years (Older
Normals, ON) was used as a comparison group. CSF BDNF level
was lower in AD patients compared to ON with a mean difference
of 25 pg/ml (post-hoc Bonferroni test, p=0.02). CSF BDNF level
for the nine MCI patients was not different from either group
(both p.0.05). The frequencies of Met-BDNF genotype (G/G vs.
G/A or A/A) were not different between ON, MCI, and AD
subjects (Fisher’s Exact Test p=0.36). Moreover, CSF BDNF
concentration in AD subjects was not different among Met-BDNF
genotype G/G (70%, 217638 pg/ml), G/A (25%, 214639 pg/
ml), or A/A (5%, 213 pg/ml, n=1) (F=0.02, df=2, p=0.99).
CSF BDNF concentration in all cognitively normal
subjects
Our focus was on 128 cognitively normal volunteers (Normals)
in whom we measured CSF BDNF, Ab42, and total tau, and who
underwent neuropsychological evaluation (Table 1). CSF BDNF
concentration was not different among rs6265 genotype in
Normals: G/G (60%, 242637 pg/ml), G/A (36%, 253626 pg/
ml), or A/A (5%, 251628 pg/ml) (F=1.52, df=2, p=0.22).
CSF BDNF concentration decreased with age among Normals
and was higher in women than men (both p,0.001; Figure 1). In
a multivariate linear regression with CSF BDNF as the dependent
variable and age, gender, presence of the APOE e4 allele, and Met-
BDNF (G/G vs G/A or A/A) as independent predictors, both age
and gender were significantly associated with CSF BDNF level
(p,0.001). Neither presence of APOE e4 allele (p=0.33) nor Met-
BDNF (p=0.09) was related to CSF BDNF levels. In addition,
there was no interaction between APOE e4 allele and Met-BDNF
genotype (p=0.25), nor between age and gender (p=0.45).
Removing the three lowest values of BDNF for males did not
change the results. Finally, after adjusting for age and gender, CSF
BDNF levels were related inversely (slope=20.03) to CSF levels
of Ab42 (p=0.05) but not to CSF total tau (p=0.34).
Association between CSF BDNF concentration, memory,
and cognitive ability in cognitively normal subjects at
baseline. Most (n=121) Normals underwent extensive
neuropsychological testing at baseline (Table 1). Table 2 shows
the regression coefficients and p-values associated with baseline
CSF BDNF levels for each cognitive test in multivariate regression
models after adjusting for age, gender, and years of education








Number 1 2 8 5 07 69 2 1
Age, years, mean6SD (Range) 52620 (21–100) 7269 (41–100) 67610 (50–100) 7468 (63–82) 68610 (52–87) 0.14
Gender, male % 49 46 43 67 48 0.45
Race, Caucasian %* 90 90 89 100 95 0.29
APOE Genotype, any e4 %* 30 28 35 78 65 0.004
BDNF Genotype rs6265 G/A or A/A %* 40 34 39 12 30 0.36
Education, years mean6SD*1 6 631 6 631 6 631 6 631 5 63 0.33
BDNF, pg/ml, mean6SD 246633 233635 240636 241636 216635 0.02
MMSE, mean6SD 29612 9 612 9 612 8 612 0 65
ON: Older Normals; MCI: Mild Cognitive Impairment; AD: Alzheimer disease; MMSE: Mini-Mental State Exam.
*Missing Values. Race – 1 (AD). APOE – 2 (one ON, one AD). BDNF Genotype – 4 (two ON, one MCI, one AD). Education – 1 (AD).
**p-value based on one-way ANOVA for continuous variables and Fisher’s exact test for categorical variables. No comparison between groups was performed for MMSE
since this test is used for diagnosis.
doi:10.1371/journal.pone.0005424.t001
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concentration of CSF Ab42 and total tau (biomarkers of latent
and prodromal AD [18,19], Model 2); and adjusting for the
previous variables as well as presence of APOE e4 and Met-BDNF
(Model 3). There was an association between higher CSF BDNF
concentrations and better performance on Paragraph Recall -
Delayed that was independent of CSF Ab42 and total tau
concentrations (Model 2) as well as presence of APOE e4 and
Met-BDNF (Model 3); correlation with the Paragraph Recall -
Immediate was significant when all predictor variables were in the
model (Model 3). An association between lower CSF BDNF and
poor performance on Trail Making Test Part B also was observed.
There was no significant correlation between CSF BDNF
concentration and performance on the Category Fluency test.
Association between baseline CSF BDNF concentration
and longitudinal changes in cognitive performance. Fifty
Normals (27 women), aged 40–100 years (mean6SD=71.568.9)
had at least one clinical follow-up visit (mean6SD 4.061.1,
Range=2–6) with an average length of follow-up of 3.3 years
(SD=1.2 years, Range=0.7–5.8 years) (Table 1). Figure 2
shows unadjusted annual changes in cognitive test scores versus
baseline CSF BDNF concentration. After adjusting for age,
gender, years of education, and baseline test score, lower values
of baseline BDNF concentration were significantly associated with
greater annual decline in Immediate and Delayed Recall scores on
the Paragraph Recall test, and a greater annual decline in the
Category Fluency test (Model 4). These relationships were
unchanged after further adjusting for baseline CSF Ab42 and
total tau concentrations (Model 5), suggesting that prediction by
baseline CSF BDNF concentration for subsequent cognitive
changes is independent of preclinical AD. These relationships
also were unchanged after further adjusting for presence of APOE
e4 and Met-BDNF (Model 6). All results were unaffected by
removing the subject who had the largest annual decline for
Immediate Recall, Delayed Recall, and Category Fluency
(Figure 2).
Figure 1. Cross-sectional relationships between age and CSF BDNF concentration by gender.
doi:10.1371/journal.pone.0005424.g001
Table 2. Relationships between baseline CSF BDNF concentration with cross-sectional and longitudinal cognitive performance.
Cross-sectional (n=121) Longitudinal (n=50)
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
Paragraph Recall: Immediate
Recall
0.17 (0.11); 0.13 0.22 (0.12); 0.06 0.26 (0.12); 0.03 0.09 (0.04); 0.02 0.11 (0.04); 0.01 0.13 (0.04); ,0.01
Paragraph Recall: Delayed
Recall
0.32 (0.11); ,0.01 0.39 (0.11); ,0.01 0.43 (0.10); ,0.01 0.13 (0.05); ,0.01 0.13 (0.05); 0.01 0.15 (0.05); ,0.01
Category Fluency: Animal 20.08 (0.19); 0.67 0.02 (0.19); 0.93 0.06 (0.19); 0.73 0.16 (0.06); 0.01 0.19 (0.06); ,0.01 0.21 (0.07); ,0.01
Log10 Trail Making test: Part B 20.009 (0.005); 0.07 20.013 (0.005); 0.02 20.011 (0.005); 0.03 20.001 (0.001); 0.42 20.002 (0.001); 0.14 20.002 (0.001); 0.11
Data are: linear regression model coefficient (SE) per10 pg/ml; p-value. Models 1, 2, and 3: Cross-sectional relationships between baseline CSF BDNF concentration
and coincident cognitive test scores in 121 Normals with baseline neuropsychological testing. Model 1: adjusted for age, gender, and years of education. Model 2:
Model 1 plus CSF Ab42 and total tau concentrations. Model 3: Model 2 plus APOE e4( e42 vs. e4+) and Met-BDNF genotype (G/G vs. G/A or A/A) (n=119 because of two
missing values for rs6265 genotype). Models 4, 5 and 6: longitudinal relationships between baseline CSF BDNF concentration and subsequent annual change in
cognitive test scores for 50 Normals with follow-up evaluation. Model 4: adjusted for age, gender, years of education, and baseline test score. Model 5: Model 4 plus
baseline CSF Ab42 and total tau concentrations. Model 6: Model 5 plus APOE e4( e42 vs. e4+)a n dMet-BDNF genotype (G/G vs. G/A or A/A).
doi:10.1371/journal.pone.0005424.t002
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performance in the Normals
Among all Normals (n=119; 2 missing values for genotype),
baseline performance on each of the four cognitive tests
(Immediate and Delayed Recall, Category Fluency, and Trail
Making Part B) did not differ by Met-BDNF genotype (G/G vs. G/A
or A/A, all p.0.05), even after adjusting for age, gender and
education in the multiple regression model (all p.0.05). Similarly,
the longitudinal changes in these cognitive performances (n=50)
were not associated with Met-BDNF genotype (all p.0.05).
Discussion
We made three novel observations in cognitively normal
individuals. (i) CSF BDNF decreased across the human life-span
in the absence of dementia or MCI and was independent of
inheritance of Met-BDNF or the APOE e4 allele. (ii) Women had
higher average CSF BDNF concentrations than men. (iii) Lower
CSF BDNF concentration was associated strongly with poorer
memory and less so with diminished executive function;
importantly, these associations were independent of CSF bio-
markers of preclinical AD, suggesting that the mechanisms that
contribute to early AD and to age-related decline in CSF BDNF
might be independent. We must acknowledge that this study has a
relatively small sample size and short duration of follow-up and
further studies are needed to validate our results.
While ours is the first study of which we are aware to investigate
age-related changes in CSF BDNF, other studies have investigated
disease-associated changes in CSF BDNF in patients with
idiopathic Parkinson disease [7,20] or in patients with AD
[7,21,22]. We confirmed that CSF BDNF is further reduced
beyond age-related decline in patients with probable AD. CSF and
serum BDNF concentrations do not correlate [23]; yet, increased
and decreased serum BDNF levels are related to early and late
stages, respectively, of AD [24].
The gender difference in CSF BDNF observed in this study is
especially interesting, and we speculate that this may be due to
hormonal effects. Animal studies have shown that estrogen
receptors colocalize to cells that express BDNF and its receptor
trkB, and estrogen regulates the expression of BDNF [25]. The
relationship between estrogen levels and BDNF expression and
secretion, and their potential effect on the cognition in humans
requires further studied.
Our data showed that progressive decline in CSF BDNF
concentration was a feature of advancing age independent of
preclinical AD or dementia, and was associated strongly with
Figure 2. Annual change in cognitive test scores versus baseline CSF BDNF concentration.
doi:10.1371/journal.pone.0005424.g002
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with performance on tests of executive function, perhaps a
reflection of the special role of BDNF in hippocampal function.
Age-related reduction in CSF BDNF was independent of
inheritance of Met-BDNF or APOE e4. Further reduction in CSF
BDNF occurred in AD. Our data suggest that reduced secretion of
BDNF in the central nervous system is one mechanism that may
contribute to age-related cognitive decline.
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